

Isaac Shariv
Einat Zisman
Amir Naiberg
Yaacov Cohen
Ruth Granoth

Scientific Breakthroughs for the Public Benefit

Department of Biological Chemistry

Tel. 972 8 934 0617 Fax. 972 8 934 4112

E-mail: info.yeda@weizmann.ac.il

Web page: <http://yeda.weizmann.ac.il>

Yeda Research and Development Company Ltd. functions as the commercial arm of the Weizmann Institute of Science. Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by Institute scientists.

Yeda holds an exclusive agreement with the Weizmann Institute to market and commercialize its intellectual property and generate income to support further research and education.

Yeda performs the following activities:

- Identifies and assesses research projects with commercial potential.
- Protects the intellectual property of the Institute and its scientists.
- Licenses the Institute's inventions and technologies to industry.
- Channels funding from industry to research projects

Spanning the Natural Sciences

Weizmann Institute research and technologies cover a broad spectrum of the natural sciences, including:

- Life Sciences and Biotechnology
- Agriculture and Plant Genetics
- Chemistry and Nanotechnology
- Environmental Sciences and Solar Energy
- Physics and Electro-Optics
- Mathematics and Computer Science

Proven Commercial Success

Since its establishment in 1959, Yeda has entered into formal agreements with prominent investment groups and commercial enterprises, including several large multinational corporations. Products and processes successfully transferred to industry include:

- **Copaxone®** (glatiramer acetate), a synthetic copolymer for the treatment of multiple sclerosis, licensed to Teva Pharmaceuticals Ltd.
- **Frone®** (native interferon beta), licensed to Inter-Lab Ltd., a Serono company, and used as an antiviral and anti-cancer drug, with sales exceeding \$40 million annually, until replaced by Rebif®.
- **Rebif®** (recombinant interferon beta), identical to the native molecule and registered for the treatment of multiple sclerosis, licensed to Inter-Lab Ltd., a Serono company.
- **Dunaliella** (beta-carotene), a health food product with possible anti-cancer properties, extracted from Dunaliella, a local algae, licensed to Nikken Sohonsa Corporation.
- **Encryption Algorithm** licensed to NDS Ltd., widely used as the basis for television set-top box smart cards.
- **GeneCards®**, a bioinformatics database, licensed to Xennex Inc.
- **Improved crop varieties** and hybrid cultivars of cucumbers and melons, under license to Israeli seed companies.

Yeda has also participated in the establishment of a large number of companies for development of institute discoveries, including **XTL**, **NDS**, **Proneuron**, and **Portman** (later merged with Pector).

Seeking Additional Partners

Yeda holds a diverse portfolio of technologies for which it is currently seeking industrial partners.

Additional information on the business opportunities offered by Yeda, can be found at:
<http://yeda.weizmann.ac.il>